Skip to content
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Nephrology

Hypomagnesemia 7 (ADKH-RRAGD): A Patient Guide

At a Glance

Hypomagnesemia 7 (ADKH-RRAGD) is a rare inherited RRAGD-related disorder in which the kidneys lose magnesium and potassium. Some people also develop dilated cardiomyopathy, so ongoing kidney, heart, and genetic specialist monitoring is important.

Hypomagnesemia 7—often referred by its scientific shorthand ADKH-RRAGD—is an ultra-rare genetic condition that disrupts how your body handles vital minerals. At its core, the condition is caused by a pathogenic variant in the RRAGD gene. This gene provides instructions for a protein that helps cells sense nutrients and manage growth. Current experimental models suggest that when this gene is altered, it alters cellular signaling, which interferes with the normal function of cells, primarily in the kidneys and sometimes the heart [1].

The most consistent feature of this condition is a tubulopathy, a term for a disorder in the tiny tubes of the kidneys. In ADKH-RRAGD, these tubes fail to recycle magnesium and potassium back into the blood, instead flushing them out of the body as waste. This “electrolyte wasting” can lead to persistently low levels of magnesium and potassium, which are essential for muscle function and heart rhythm [2]. While some similar kidney disorders consistently cause massive calcium buildup in the kidneys, calcium levels in the urine can vary widely in RRAGD; some patients have normal or low calcium in their urine, while others may have excess calcium that requires individualized monitoring [3].

For some individuals, the condition also extends to the heart muscle, leading to dilated cardiomyopathy (DCM). In these cases, the heart’s main pumping chamber becomes enlarged and the muscle walls weaken, making it more difficult to circulate blood effectively. The risk and severity of heart involvement are highly variable; while some people experience severe symptoms in early childhood, others may have no heart issues at all or develop them much later in life [1]. This variability appears linked to the specific pathogenic variant a person carries [4].

Because the condition is reported in only a small number of families worldwide and affects two critical organ systems, management requires a multidisciplinary care team. This group typically includes a nephrologist (kidney specialist) to manage electrolyte replacement, a cardiologist (heart specialist) to monitor heart strength, and a medical geneticist to help navigate the implications for the patient and their family [1]. While current treatments focus on replacing lost minerals and supporting heart function, staying connected with these specialists ensures that your care is proactive and tailored to your specific clinical findings and genetic profile [3].

Common questions in this guide

What is Hypomagnesemia 7 (ADKH-RRAGD)?
It is a very rare inherited condition caused by a disease-causing change in the RRAGD gene. It mainly affects the kidney tubes that normally return magnesium and potassium to the blood, and it can sometimes affect the heart.
Why are magnesium and potassium low in this condition?
The kidney tubes do not recycle these minerals normally, so more magnesium and potassium leave the body in urine. This electrolyte wasting can require blood tests and mineral replacement.
Can Hypomagnesemia 7 cause dilated cardiomyopathy?
Yes, some people develop dilated cardiomyopathy, in which the heart’s main pumping chamber enlarges and the muscle becomes weaker. Heart involvement varies widely: it may be severe in early childhood, appear later, or not occur, and the RRAGD variant may influence risk.
What treatment and monitoring does ADKH-RRAGD require?
Treatment focuses on replacing lost minerals and supporting heart function when needed. Care commonly involves a nephrologist, cardiologist, and medical geneticist, with monitoring tailored to blood mineral levels, heart function, and the person’s genetic findings.
Does everyone with RRAGD-related hypomagnesemia have high urine calcium?
No. Urine calcium can be normal, low, or high in this condition, so calcium monitoring and treatment need to be individualized.

Get notified when new evidence is published on hypomagnesemia 7, renal, with or without dilated cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (4)
  1. 1

    RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.

    Trepiccione F, Sambri I, Ruggiero B, et al.

    Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.

    PMID: 38901414
  2. 2

    mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.

    Schlingmann KP, Jouret F, Shen K, et al.

    Journal of the American Society of Nephrology : JASN 2021; (32(11)):2885-2899 doi:10.1681/ASN.2021030333.

    PMID: 34607910
  3. 3

    Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.

    Adella A, Jouret F, Madariaga L, et al.

    Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.

    PMID: 41141537
  4. 4

    RRAGD variants cause cardiac dysfunction in a zebrafish model.

    Adella A, Tengku F, Arjona FJ, et al.

    American journal of physiology. Heart and circulatory physiology 2024; (327(5)):H1187-H1197 doi:10.1152/ajpheart.00705.2023.

    PMID: 39331021

This page explains RRAGD-related hypomagnesemia for informational purposes and does not replace medical advice. A nephrologist, cardiologist, and medical geneticist should interpret your results and determine your monitoring and treatment plan.